|
1）Ikeda Y, Hoshijima M, Chien KR. Toward biologically targeted therapy of calcium cycling defects in heart failure. Physiology (Bethesda). 2008; 23: 6-16
|
|
|
|
2）Yano M, Ikeda Y, Matsuzaki M. Altered intracellular Ca2+ handling in heart failure. J Clin Invest. 2005; 115: 556-64
|
|
|
|
|
|
3）Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res. 2012; 110: 1646-60
|
|
|
|
|
|
4）Cruickshank JM. Phosphodiesterase III inhibitors: long-term risks and short-term benefits. Cardiovasc Drugs Ther. 1993; 7: 655-60
|
|
|
|
|
|
5）del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001; 104: 1424-9
|
|
|
|
|
|
6）Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002; 8: 864-71
|
|
|
|
|
|
7）Schmidt U, del Monte F, Miyamoto MI, et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation. 2000; 101: 790-6
|
|
|
|
|
|
8）Clark RJ, McDonough PM, Swanson E, et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem. 2003; 278: 44230-7
|
|
|
|
|
|
9）Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000; 97: 793-8
|
|
|
|
|
|
10）Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011; 477: 601-5
|
|
|
|
|
|
11）Yamada M, Ikeda Y, Yano M, et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J. 2006; 20: 1197-9
|
|
|
|
|
|
12）Miyazaki Y, Ikeda Y, Shiraishi K, et al. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling. PLoS One. 2012; 7: e35875
|
|
|
|
|
|
13）Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011; 124: 304-13
|
|
|
|
|
|
14）Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: 1977-2016
|
|
|
|
|
|
15）Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest. 2013; 123: 53-61
|
|
|
|
|
|
16）Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002; 303: 592-600
|
|
|
|
|
|
17）Micheletti R, Palazzo F, Barassi P, et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol. 2007; 99: 24A-32A
|
|
|
|
|
|
18）Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008; 51: 2276-85
|
|
|
|
|
|
19）Paolocci N, Katori T, Champion HC, et al. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A. 2003; 100: 5537-42
|
|
|
|
|
|
20）Froehlich JP, Mahaney JE, Keceli G, et al. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry. 2008; 47: 13150-2
|
|
|
|
|
|
21）Lancel S, Zhang J, Evangelista A, et al. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ Res. 2009; 104: 720-3
|
|
|
|
|
|
22）Wang MJ, Mazhari R, Ilsar I, et al. Intravenous infusion of CXL-1020, a novel nitroxyl (HNO) donor, improves left ventricular systolic and diastolic function in dogs with advanced heart failure. J Card Fail. 2009; 15: S73-4
|
|
|
|
|